Clinical trials
Immunity clinical trials
Below are recruiting immunity clinical trials, each written for real people, not researchers. We’re tracking 1,022 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06643221RecruitingEarly Phase 1
Exercise as a booster for cell therapy treatments
This trial tests whether exercise and a heart medicine called isoproterenol can help your immune system work better with donor cell therapies. It may show how to make these treatments more effective.
Tucson, ArizonaAges 21–55 - NCT06658834RecruitingPhase 2
Romiplostim for newly diagnosed ITP in adults
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06662110Recruiting
Blood test to predict chemo and immunotherapy response in stomach cancer
This trial tests whether a blood test (called immune proteomics) can predict how well chemotherapy and immunotherapy work in people with stomach cancer. If you qualify, you would receive standard chemo or chemo plus immunotherapy before surgery, and researchers will study your blood to see if it can guide future treatment.
Xuhui District, Shanghai MunicipalityAges 18–75 - NCT06664151RecruitingEarly Phase 1
Flu vaccine injected into skin cancer before surgery
This study tests whether injecting the seasonal flu vaccine directly into a skin cancer tumor can help the immune system attack it. You would receive the injection before your scheduled surgery to remove the cancer.
Boston, MassachusettsAges 18 years+ - NCT06667063Recruiting
Immune response study for COVID-19 and flu
This study looks at how your immune system responds to COVID-19 or the flu. It may help researchers understand these infections better, whether you are currently sick or healthy.
Wuhan, HubeiAges 18 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06675201RecruitingPhase 2
Personalized vaccine for advanced esophageal cancer after treatment
This trial tests a personalized vaccine made from your tumor's unique markers (neoantigens) to help prevent your advanced esophageal cancer from coming back. It's for people who have already completed strong treatment and are currently cancer-free, but have a high risk of recurrence.
Chengdu, Please SelectAges 18–80 - NCT06675643Recruiting
Remote monitoring of side effects from melanoma treatment
This study tests a smartphone app called Vigilant that helps monitor side effects from a melanoma treatment (ipilimumab and nivolumab). You may be able to join if you are about to start this therapy.
Rochester, MinnesotaAges 18 years+ - NCT06683248Recruiting
Night shifts and menstrual cycle health study
This study looks at how working night shifts affects your health throughout your menstrual cycle. It aims to help understand the risks and support better health for shift workers.
Uppsala, Uppsala CountyAges 18–35 - NCT06686927RecruitingPhase 2
Steroids, IVIG, and romiplostim for severe ITP
This study tests a combination of three treatments—steroids, IVIG, and romiplostim (Nplate)—for adults with severe, newly diagnosed ITP that hasn't responded well to standard therapy. The goal is to see if this triple therapy can quickly raise platelet counts and stop bleeding.
Wuhan, HubeiAges 18–75 - NCT06687694Recruiting
How antipsychotics affect the immune system in psychosis
This study looks at how antipsychotic medicines affect the immune system in people with psychosis. By taking blood samples before and after starting or changing medication, researchers hope to understand why some people respond better to treatment.
London, United KingdomAges 18–65 - NCT06689800Recruiting
Family communication tool for kids getting transplant or cell therapy
This study looks at a family communication tool for children and teens getting stem cell transplants or cellular therapy. It helps families talk about treatment together.
St Louis, MissouriAges 8 years+ - NCT06702449RecruitingPhase 1/Phase 2
UTI vaccine safety and immune response study for adults 18-64
This trial tests a new vaccine to prevent urinary tract infections (UTIs). It first checks safety and immune response in healthy adults, then in women with recent E. coli UTIs. The goal is to see if the vaccine can reduce future infections.
Lenexa, KansasAges 18–64 - NCT03501576Recruiting
Testing a flu or COVID vaccine response in people with lymphoma
This study checks how your immune system responds after getting a vaccine. It focuses on people with different types of lymphoma, aiming to learn which immune responses can be measured and whether the vaccines are safe for you.
Atlanta, GeorgiaAges 18 years+ - NCT00001467Recruiting
Study of genes in immune disorders
This research looks at how inherited (genetic) changes may affect the immune system in people with immune problems. It may help by improving understanding of these conditions and, in some cases, guiding faster care for a baby after birth.
Bethesda, MarylandAges 1 day–101 years - NCT07688759Recruiting
Immune response measurement for first CMV after transplant
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
Suzhou, JiangsuAges 18 years+ - NCT06715579Recruiting
Cardiac Angiosarcoma Global Registry
This study is a global registry for people with a rare heart cancer called cardiac angiosarcoma. It collects information on treatments and outcomes to help doctors better understand the disease and improve care.
YerevanAges Any age - NCT06717295Recruiting
Blood test to find cancer early and track treatment
This study uses a blood test that looks at your platelets and immune cells to find common cancers early, and for certain cancers, to monitor how well treatment is working.
RosarioAges 40–75 - NCT06718530Recruiting
Finding early markers for liver cancer in people with chronic liver disease
This study looks for substances in your blood and immune system that could help doctors find liver cancer earlier. It is for people with liver cancer caused by chronic liver problems like hepatitis C, cirrhosis, or scarring.
Aviano, PordenoneAges 18 years+ - NCT06726421RecruitingPhase 3
Systemic therapy with or without radiation for kidney cancer that has spread to a few spots
This trial compares standard systemic therapy (medication) alone versus systemic therapy plus targeted radiation to the cancer spots for people with kidney cancer that has spread to a limited number of places (up to 5 spots). It aims to see if adding radiation helps control the cancer better.
Fuzhou, FujianAges 18 years+ - NCT06727669Recruiting
Long-term study of blood clotting and bleeding disorders
This study observes patients with blood clotting or bleeding disorders over time to collect health information and improve care.
Beijing, Beijing MunicipalityAges Any age - NCT06730503Recruiting
Glycoprotein test for lung cancer immunotherapy response
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06734689Recruiting
Genes and heart inflammation from immunotherapy
This study looks at genetic factors that may affect the risk of heart inflammation (myocarditis) caused by immune checkpoint inhibitors (ICIs), a type of cancer immunotherapy. It aims to find out if your genes make you more likely to develop this side effect.
ParisAges 18 years+ - NCT06739226RecruitingPhase 1/Phase 2
Combination Immunotherapy for Advanced Melanoma
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
Shenzhen, GuangdongAges 18–75
Hear when a new Immunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunity?
- Yes. Clin2 currently lists 1,022 recruiting immunity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.